Recursion Pharmaceuticals (RXRX) Competitors

Recursion Pharmaceuticals (NASDAQ:RXRX) and Ascendis Pharma A/S (NASDAQ:ASND) are both mid-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, dividends, risk, analyst recommendations, community ranking, profitability, institutional ownership, valuation and earnings.

Is RXRX or ASND more profitable?

Ascendis Pharma A/S has a net margin of -104.54% compared to Recursion Pharmaceuticals' net margin of -579.52%. Ascendis Pharma A/S's return on equity of 0.00% beat Recursion Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Recursion Pharmaceuticals	-579.52%	-76.56%	-55.68%
Ascendis Pharma A/S	-104.54%	N/A	-39.23%

Do analysts recommend RXRX or ASND?

Recursion Pharmaceuticals currently has a consensus price target of $8.25, indicating a potential upside of 26.83%. Ascendis Pharma A/S has a consensus price target of $204.64, indicating a potential upside of 25.75%. Given Recursion Pharmaceuticals' higher probable upside, analysts clearly believe Recursion Pharmaceuticals is more favorable than Ascendis Pharma A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Recursion Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.40
Ascendis Pharma A/S	0 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.93

Which has more volatility and risk, RXRX or ASND?

Recursion Pharmaceuticals has a beta of 0.85, meaning that its stock price is 15% less volatile than the S&P 500. Comparatively, Ascendis Pharma A/S has a beta of 0.62, meaning that its stock price is 38% less volatile than the S&P 500.

Do insiders and institutionals hold more shares of RXRX or ASND?

89.1% of Recursion Pharmaceuticals shares are owned by institutional investors. 15.8% of Recursion Pharmaceuticals shares are owned by insiders. Comparatively, 40.0% of Ascendis Pharma A/S shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Does the MarketBeat Community believe in RXRX or ASND?

Ascendis Pharma A/S received 417 more outperform votes than Recursion Pharmaceuticals when rated by MarketBeat users. Likewise, 66.82% of users gave Ascendis Pharma A/S an outperform vote while only 55.56% of users gave Recursion Pharmaceuticals an outperform vote.

Company	Underperform	Outperform
Recursion Pharmaceuticals	Outperform Votes 30 55.56%	Underperform Votes 24 44.44%
Ascendis Pharma A/S	Outperform Votes 447 66.82%	Underperform Votes 222 33.18%

Does the media prefer RXRX or ASND?

In the previous week, Recursion Pharmaceuticals had 1 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 8 mentions for Recursion Pharmaceuticals and 7 mentions for Ascendis Pharma A/S. Ascendis Pharma A/S's average media sentiment score of 0.84 beat Recursion Pharmaceuticals' score of 0.84 indicating that Ascendis Pharma A/S is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Recursion Pharmaceuticals	4 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ascendis Pharma A/S	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has preferable valuation and earnings, RXRX or ASND?

Recursion Pharmaceuticals has higher earnings, but lower revenue than Ascendis Pharma A/S. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than Recursion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Recursion Pharmaceuticals	$58.49M	44.71	-$328.07M	-$1.66	-3.92
Ascendis Pharma A/S	$363.64M	27.16	-$409.12M	-$7.10	-22.92

Summary

Ascendis Pharma A/S beats Recursion Pharmaceuticals on 10 of the 18 factors compared between the two stocks.